For Immediate Release, April 04, 2003

Affinium™ Pharmaceuticals Congratulates Dr. Aled Edwards on his Appointment to Lead the Structural Genomics Consortium

Affinium Founder to Lead Not-for-Profit Institution

TORONTO, ONTARIO (April 4, 2003) – Affinium Pharmaceuticals, Inc., a leader in structure guided drug discovery, congratulates Dr. Aled Edwards on his appointment to the Chief Executive Officer in the not-for-profit Structural Genomics Consortium (SGC). The SGC is an Anglo-Canadian partnership whose mission is to increase the number of public domain protein structures for life sciences and biomedical research. The SGC will operate from research laboratories at the Universities of Oxford and Toronto, and collaborate with the European Bioinformatics Institute in Cambridge.

“The SGC represents a rare opportunity for Dr. Edwards to impact science on an international level.,” said Dr. John D. Mendlein, Affinium’s Chairman and CEO. “This appointment reflects Al’s stature in the scientific community. We celebrate his new academic endeavors, as well as his past and future contributions to our Company.” Dr. Edwards will continue to devote twenty percent of his time to Affinium as Scientific Advisor.

Affinium Pharmaceuticals is a structure guided drug discovery company. Affinium’s pharmaceutical pipeline includes discovery programs in infectious disease and against a target family. The Company’s proprietary, integrated R&D engine is designed for rapid advancement of small molecule programs from gene to clinic. The Company’s R&D engine enables high throughput target production, determination of target function, and visualization of target structure with bound hits and leads to accelerate chemistry in the discovery of new medicines. The Company also integrates the premier discovery capabilities of Vertex pharmaceuticals and Albany Molecular Research to advance Affinium’s internal drug discovery efforts. The Company’s investors include the Lombard Odier Immunology Fund, Schweizerhall Holding AG, Ultreia Capital, Genesys Capital Partners Inc., and HBM BioVentures, as well as industrial partners GSK Ventures, Albany Molecular Research Inc., Vertex and the Bruker Companies.

Affinium and Affinium Pharmaceuticals are trademark names of Affinium Pharmaceuticals, Inc.

For more information, please contact:

Affinium™ Pharmaceuticals
100 University Avenue
12th Floor, North Tower
Toronto, Ontario,
Canada
M5J 1V6

Executive Contact: Dr. John D. Mendlein
Corporate Communications Contact: Dr. Joanne E. Harack
T: (416) 645-6600
FAX: (416) 598-1262
jharack@afnm.com
www.afnm.com